Population pharmacokinetics (PK) of ritonavir (RTV)-boosted atazanavir (ATV) in HIV-infected and healthy individuals

被引：0
|
作者：
Dickinson, L. [1 ,3 ]
Aarons, L. [2 ]
Back, D. [3 ]
Waters, L. [4 ]
Else, L. [3 ]
Khoo, S. [3 ]
Pozniak, A. [4 ]
Boffito, M. [4 ]
机构：
[1] Royal Liverpool & Broadgreen Univ Hosp Trust, NIHR Biomed Res Ctr, Liverpool, Merseyside, England
[2] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester, Lancs, England
[3] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England
[4] Chelsea & Westminster Fdn Trust, St Stephens Ctr, London, England
来源：
HIV MEDICINE | 2009年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：51 / 52
页数：2
相关论文
共 50 条
  • [11] Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients
    Mallolas, J.
    Sarasa, M.
    Nomdedeu, M.
    Soriano, A.
    Lopez-Pua, Y.
    Blanco, J. L.
    Martinez, E.
    Gatell, J. M.
    [J]. HIV MEDICINE, 2007, 8 (02) : 131 - 134
  • [12] COST-EFFECTIVENESS OF ATAZANAVIR/RITONAVIR (ATV plus RTV) COMPARED WITH LOPINAVIR/RITONAVIR (LPV plus RTV) IN TREATMENT-NAIVE HIV-INFECTED PATIENTS IN MEXICO: A MODEL BASED ON THE CASTLE STUDY
    Juarez-Garcia, A.
    Martinez-Rivera, G.
    Donato, B. M.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A117 - A118
  • [13] Concomitant intake of tenofovir disoproxil fumarate (TDF) does not impair plasma exposure of ritonavir (RTV) boosted atazanavir (ATV) in HIV-1 infected adults.
    Hentig, NV
    Haberl, A
    Lutz, T
    Klauke, S
    Kurowski, M
    Harder, S
    Staszewski, S
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P18 - P18
  • [14] Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents
    Foissac, Frantz
    Blanche, Stephane
    Dollfus, Catherine
    Hirt, Deborah
    Firtion, Ghislaine
    Laurent, Corinne
    Treluyer, Jean-Marc
    Urien, Saik
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (06) : 940 - 947
  • [15] Ritonavir-boosted atazanavir may be efficacious in HIV-infected patients concurrently receiving omeprazole
    Chan-Tack, KM
    Edozien, A
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 42 (09) : 1344 - 1344
  • [16] Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir
    Guiard-Schmid, JB
    Poirier, JM
    Bonnard, P
    Meynard, JL
    Slama, L
    Lukiana, T
    Jaillon, P
    Pialoux, G
    [J]. AIDS, 2005, 19 (16) : 1937 - 1938
  • [17] Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir
    Meynard, JL
    Poirier, JM
    Bonnard, P
    Meynard, JL
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (03) : 393 - 394
  • [18] Population Pharmacokinetics of Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients
    Lopez Aspiroz, Elena
    Santos Buelga, Dolores
    Cabrera Figueroa, Salvador
    Lopez Galera, Rosa Maria
    Ribera Pascuet, Esteban
    Dominguez-Gil Hurle, Alfonso
    Garcia Sanchez, Maria Jose
    [J]. THERAPEUTIC DRUG MONITORING, 2011, 33 (05) : 573 - 582
  • [19] Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients
    Custodio, Joseph M.
    Gordi, Toufigh
    Zhong, Lijie
    Ling, Kah Hiing J.
    Ramanathan, Srini
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (06): : 723 - 732
  • [20] Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients
    Waters, Laura J.
    Moyle, Graeme
    Bonora, Stefano
    D'Avolio, Antonio
    Else, Laura
    Mandalia, Sundhiya
    Pozniak, Anton
    Nelson, Mark
    Gazzard, Brian
    Back, David
    Boffito, Marta
    [J]. ANTIVIRAL THERAPY, 2007, 12 (05) : 825 - 830
12345